Results 151 to 160 of about 3,791 (213)

Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data

Journal of Nuclear Medicine
Visual Abstract Before performing 177Lu-DOTATATE therapy for neuroendocrine tumors, somatostatin receptor (SSTR) PET imaging is currently used to confirm sufficient tumor SSTR expression, but it also has potential to be used to personalize treatment by ...
Azadeh Akhavanallaf, Zhonglin Lu, Avery B. Peterson, J. Blakkisrud, Sara Kurkowska, Surekha Yadav, Chang Wang, Carlos Uribe, C. Stokke, A. Rahmim, Ka Kit Wong, J. Beauregard, Thomas A. Hope, Katarina Sjögreen Gleisner, Y. Dewaraja   +14 more
semanticscholar   +1 more source

177Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trial.

Annals of Oncology
BACKGROUND The phase III trial, XT-XTR008-3-01, was a randomised controlled trial (RCT) that evaluated the efficacy and safety of XTR008, a novel no-carrier-added lutetium-177 (177Lu)-Dotatate, for the first time in a later-line therapy setting for ...
J. Xu, J. Chen, S. Song, L. Song, R. Wang, J. Hao, X. Du, D. Cao, Y. Gao, X. Lan, A. Yang, W. Miao, H. Xu, Y. Chen, L. Li, H. Shi, X. Yuan, F. Ye, J. Wang, N. Xu, X. Han, X. Li, R. Huang, T. Zhang, E. Li, Y. Zhou, H. Chen, X. Zhu, J. Zhao, X. Su, Y. Cui, P. Ren, P. Wang   +32 more
semanticscholar   +1 more source

Clinical Outcomes of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Skeletal Metastases from Neuroendocrine Tumors: Insights from Real-World Experience

Journal of Nuclear Medicine
Visual Abstract Skeletal metastases portend a poor prognosis for patients with neuroendocrine tumors (NETs). Literature on peptide receptor radionuclide therapy (PRRT) specific to patients with skeletal metastases from NETs is scarce. This study assessed
K. Chandekar, S. Satapathy, Sanjana Ballal, M. Yadav, S. Ravindra, S. Rastogi, R. Sahoo, C. Bal   +7 more
semanticscholar   +1 more source

[Clinical Practice of 177Lu-DOTATATE in the Treatment of Neuroendocrine Tumors].

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2023
Most of the neuroendocrine tumors(NETs) overexpress the somatostatin receptor(SSTR),which provides a reliable target for SSTR-targeted peptide receptor radionuclide therapy(PRRT).Compared with drug therapy,PRRT has high objective response rate and significantly prolongs patients' survival.Moreover,the patients have good tolerance to this therapy ...
Li-Meng, He, Ying, Deng, An-Bo, Wang, Nan, Liu, Yue, Chen, Xue-Xian, Yan, Wei, Zhang   +6 more
openaire   +1 more source

Radiation absorbed dose efficacy of 177Lu-DOTATATE in radionuclide therapy of neuroendocrine tumors: a hybrid study of patient and simulation.

Radiation Protection Dosimetry
Recent developments in targeted radiopharmaceuticals offer promising options for diagnosis and treatment by specifically targeting the overexpressed somatostatin receptors in neuroendocrine tumors (NETs).
Alireza Seyedabadi, P. Porouhan, H. Sadoughi, Ruhollah Ghahramani-Asl   +3 more
semanticscholar   +1 more source

Esthesioneuroblastoma (Olfactory Neuroblastoma) Treated With 111In-Octreotide and 177Lu-DOTATATE PRRT

Clinical Nuclear Medicine, 2015
A 51-year-old man with a recurrent metastatic esthesioneuroblastoma (olfactory neuroblastoma) was referred for peptide receptor radionuclide therapy (PRRT). He received 4 treatments of 111In-octreotide over 8 months and 3 treatments of 177Lu-DOTATATE over 4 months, which helped alleviate his symptoms and improved his quality of life; however, the tumor
William, Makis, Karey, McCann, Alexander J B, McEwan   +2 more
openaire   +2 more sources

A Multicenter Phase II Randomized Controlled Trial Comparing 177Lu-Dotatate/Capecitabine Combination Treatment with 177Lu-Dotatate Monotherapy in Patients with Neuroendocrine Tumors

Clinical Cancer Research
Abstract Purpose: Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-[DOTA0,Tyr3]octreotate (177Lu-Dotatate) is an effective and safe treatment for patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP NET). Whereas 177Lu-Dotatate prolongs progression-free survival
Morticia N. Becx, Johannes Hofland, Eric P. Krenning, David K. Wyld, Julie Nonnekens, Frederik A. Verburg, Tessa Brabander, Jan J.V. van Busschbach, Wouter W. de Herder   +8 more
openaire   +5 more sources

Extraventricular Neurocytoma Treated With 177Lu DOTATATE PRRT Induction and Maintenance Therapies

Clinical Nuclear Medicine, 2015
A 64-year-old woman with a 30-year history of recurrent sellar masses presented with severe headache and rapidly progressive visual field loss in the left eye. She was diagnosed with an extraventricular neurocytoma, which was octreotide positive, and was referred for PRRT (peptide receptor radionuclide therapy) with 177Lu [DOTA0,Tyr3]octreotate ...
William, Makis, Karey, McCann, Alexander J B, McEwan   +2 more
openaire   +2 more sources

First experience of durable cytoreduction in chronic lymphoid leukemia with 177Lu-DOTATATE

Medical Oncology, 2019
This is the first described case of effective and durable cytoreduction after PRRT with 177Lu-DOTATATE in a 75-year-old female, with B cell chronic lymphoid leukemia, and well-differentiated metastatic neuroendocrine tumor.
Savovic T, Prior JO, Nicod-Lalonde M, Bressoud A, Roux S, Schaefer N, Meyer M   +6 more
openaire   +3 more sources

Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors.

Oncology, 2011
Peptide receptor-targeted radionuclide therapy (PRRT) of somatostatin receptor (SR)-expressing neuroendocrine tumors (NETs) has become an established therapeutic option in patients with advanced NETs. The aim of this study was to compare the lesion detection rate of (99m)Tc-EDDA/HYNIC-TOC, a newly developed tracer for NET imaging, with (177)Lu-DOTATATE
Siroos, Mirzaei, Brigitte, Bastati, Rainer W, Lipp, Peter, Knoll, Niklas, Zojer, Heinz, Ludwig   +5 more
openaire   +1 more source